EntreMed Files to Begin Clinical Trial of Cancer Drug in China
EntreMed, a  Washington   DC- area biotech, has filed an application with the SFDA to begin clinical trials in  China  of its cancer treatment, ENMD-2076. The trial is a US-China Phase II test of the drug in patients with triple-negative breast cancer. EntreMed said that adding a  China  arm to the trial would shorten the time necessary for patient recruitment and save on other costs as well. More details.... Stock Symbol: (NSDQ: ENMD) Share this with colleagues: // //  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here